ICER panel says Luxturna has an intermediate value, discusses pricing models

The Midwest Comparative Effectiveness Public Advisory Council (CEPAC) voted Thursday that the long-term value of vision loss drug Luxturna voretigene neparvovec-rzyl from Spark Therapeutics Inc. (NASDAQ:ONCE) is intermediate.

The final vote consisted of two votes for a high value, seven for an intermediate value and three for a low value. The split vote demonstrates that there is still no agreement

Read the full 602 word article

User Sign In